Lavol Use In Pregnancy & Lactation

Use in Pregnancy: Due to the unavailability of drug safety data for pregnant women, the drug should not be used by pregnant women and those planning a pregnancy, unless, according to the doctor, the benefits provided outweigh the possible risks.
In drug studies on pregnant experimental animals, suppression of fetal weight gain and decreased viability of neonates was observed.
In the epidemiological survey it was stated that patients who received benzodiazepine-derived drugs during pregnancy gave birth to babies with congenital abnormalities, with a much higher rate than controls
It was reported that benzodiazepines cause symptoms such as difficulty eating, nausea, decreased activity, hypotonia, hypertonia, somnolence, respiratory depression/apnea, cyanosis, irritability, hypersensitivity, tremor, hypothermia, and tachycardia in neonates. There is a case where symptoms developed as a result of withdrawal symptoms or asphyxia in the neonate. It has also been reported that benzodiazepines showed an increase in the incidence of neonatal jaundice.
Repeated administration of other benzodiazepines (diazepam) before delivery has been reported to cause withdrawal symptoms (anxiety, tremor, hypertonia, etc.).
Use in Lactation: This drug has been reported to increase the incidence of neonatal jaundice. Therefore, it is not recommended for use in nursing mothers. If this drug must be used in nursing mothers, the patients must stop breastfeeding.
In studies on experimental animals during the lactation period, decreased viability in neonates was found.
It has been reported that another benzodiazepine (diazepam) is excreted into breast milk, causing lethargy and weight loss in infants.